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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S302gel was contained within the knee while slowly degrading over a period
of 4 weeks. Group 2: No changes in patellar cartilage quantity or quality
occurred following intra-articular gel injection (p>0.10). At t¼0;
t¼6weeks and t¼12weeks, cartilage volume L/R ratios were 1.020.12;
0.990.1; 1.08.04 respectively; for attenuation 1.040.09; 1.050.08;
1.030.13. Histology conﬁrmed that the gel did not affect the cartilage.
Group 3; sustained drug release from the gel was conﬁrmed with Cel-
ecoxib being detectable in plasma samples up to 40 days at a sustained
level of w50-100 ìg/l (ﬁgure 2).
Conclusions: Aliphatically-modiﬁed PCLA-PEG-PCLA form radiopaque
and biocompatible gels which are able to deliver encapsulated drugs
upon degradation over a period of several weeks. This system is
therefore a promising candidate for intra articular drug delivery as
a treatment for OA.
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SAFETY OF MULTIPLE MUSCULOSKELETAL INJECTIONS IN PATIENTS
TAKING WARFARIN OR WARFARIN AND ASPIRIN
S.P. Pandit y, J. Waterman z, J. Corriea x. yUniv. of Connecticut Hlth.Ctr.,
Farmington, CT, USA; zUniv. of Connecticut Sch. of Med. and the
Connecticut VA Hlth.care System, Farmington and Newington, CT, USA;
x The Connecticut VA Hlth.care System, Newington, CT, USA
Purpose: Injections involving the musculoskeletal system are
a common practice in rheumatology. Several studies have shown the
relative safety of single musculoskeletal injections (MSI) in patients
taking warfarin. This prospective study looked at repeated injections
regarding the ongoing safety of MSI in patients taking warfarin and also
in patients taking warfarin and low dose aspirin.
Methods: A total of 42 patients were entered into the study from 1/
2008 to 12/2010. There were a total of 216 injections. All patients who
had at least 2 MSI in any part of their musculoskeletal system and were
actively followed in the VA Anticoagulation Clinic were included in the
study. Patients who received only one MSI or had multiple injectionsbut were not followed by the VA Anticoagulation Clinic during the study
period were excluded. All of the patients were taking warfarin and 14
were also taking aspirin for a variety of causes. All patients were on
stable doses of warfarin and had INR levels within a month of the
injections. After receiving injections, all patients were contacted by
phone within a month of the injections, at the time of the INR check,
and directly asked if there had been any complications related to the
injections.
Results: Of the 216 injections in the 42 patients, the knee was the most
common joint injected (n¼ 91: 42.1%). Other sites of injections included
the shoulder (n ¼ 56: 25.9%); humeral epicondyle (n ¼ 6: 2.7%); small
hand joints (n ¼ 11: 5.1%); wrist (n ¼ 5: 2.3%); various bursae (n ¼ 14:
6.5%); other soft tissue sites (n ¼ 33: 15.2%) Injectates included corti-
costeroids (CS) and hyaluronate. CS injections were the most common
representing 81.8% of the total injections .The average total number of
injections per patient was 5.1. The mode was 2. INR levels ranged from
1.1 - 4.8; average INR: 2.5. Only two patients reported bruising at the
injection site. One patient was also taking aspirin. INRs in both patients
were 2.1 and 2.4. No other complications were reported and no added
complications in the patients taking both warfarin and aspirin.
Conclusions: It has been shown that single MSI are safe in patients on
warfarin. This study demonstrates that repeated injections in any site in
the musculoskeletal system are also safe in patients on warfarin and
patients on warfarin and aspirin.590
AN INNOVATIVE HYALURONIC ACID PRODUCT FOR
VISCOSUPPLEMENTATION IN PATIENTS WITH OSTEOARTHRITIS
S. Gavard. Anteis, Meyrin, Switzerland
Purpose: The speciﬁc formulation [HA+sorbitol] of Synolis V-A is
based on a high molecular weight of HA (> 2 MDa in the ﬁnal sterilized
gel) from non animal origin, with a high HA concentration (20 mg/ml),
combined with a high concentration of a free radical scavenger, the
sorbitol (40 mg/ml). The aims of this study are to evaluate the
mechanical/rheological properties and the resistance to free radicals
degradation of Synolis V-A.
Methods: The rheological properties are analyzed by frequency sweep
experiments at 25C thanks to a parallel plate rheometer (AR2000, TA
Instruments). The resistance to free radical degradation is observed
visually by adding an oxidant agent (H2O2) on the viscosupplement
(Weight of H2O2 ¼ 1/15 x Weight of viscosupplement), by heating the
mixing at 60C and by watching the ﬂow of the product over time. The
resistance to free radical degradation is also followed thanks to an
AR2000 rheometer (time sweep experiments at 37C). Results of
resistance to degradation obtained with Synolis V-A are compared to 5
other commercial viscosupplements.
Results: Visco-elastic properties of Synolis V-A. Synolis V-A is charac-
terized by a visco-elastic behavior close to the human synovial ﬂuid
(viscous and elastic moduli crossing at 0.4 Hz) and high viscous and
elastic moduli due to the high afﬁnity between HA and sorbitol that
stabilizes the structure through a very dense network of hydrogen
bonds. Resistance to free radical degradation. In presence of free radi-
cals (H2O2), Synolis V-A demonstrates a much higher resistance against
free radicals than the other commercial viscosupplements as shown by
the visual observation and by the rheological properties.
Conclusions: Synolis V-A is an innovative viscosupplement made of
hyaluronic acid and sorbitol. Due to its patented formulation and
manufacturing process, Synolis V-A has outstanding rheological prop-
erties and a high resistance against in vivo degradation in the joint. As
demonstrated by several experiments, Synolis V-A is characterized by
a visco-elastic behaviour close to the human synovial ﬂuid, a very high
elasticity and viscosity and a high resistance to free radical degradation.
The synergetic combination of HA of high molecular weight and
sorbitol, combined with a speciﬁc manufacturing process which
included a ﬁnal moist heat sterilization, allows to obtain unique prop-
erties. Moreover, due to the high afﬁnity between HA and sorbitol,
Synolis V-A is stabilized through a very dense network of hydrogen
bonds. This complex structure of gel presents remarkably high visco-
elastic properties. Consequently, thanks to these particular visco-elastic
properties, Synolis V-A has a high ability to lubricate joints and to
absorb shocks, as with a healthy synovial ﬂuid. On the other hand, the
high ability of sorbitol to scavenge and neutralize free radicals (¼
antioxidant effect) allows to limit the degradation of the gel in order to
increase the half-life of the product in the joint (as described in the
